Departments of Biobehavioral Nursing and Health Informatics; and.
Global Health, University of Washington, Seattle, WA.
J Acquir Immune Defic Syndr. 2021 Apr 1;86(4):e83-e89. doi: 10.1097/QAI.0000000000002587.
Discontinuation of daily oral pre-exposure prophylaxis (PrEP) is frequent among adolescent girls and young women (AGYW) in African settings. We explored factors influencing early PrEP discontinuation and persistence among Kenyan AGYW who accepted PrEP within a programmatic setting.
We conducted in-depth interviews with AGYW (aged 15-24 years) who accepted PrEP from 4 maternal child health (MCH) and family planning (FP) clinics. AGYW were identified by nurses at routine clinic visits and purposively sampled based on 4 categories: (1) accepted PrEP pills, but never initiated PrEP use (eg, never swallowed PrEP pills), (2) discontinued PrEP <1 month after initiation, (3) discontinued PrEP within 1-3 months, and (4) persisted with PrEP use >3 months. Informed by the Stages of Change Model, thematic analysis characterized key influences on PrEP discontinuation/persistence.
We conducted 93 in-depth interviews with AGYW who accepted pills. Median age was 22 years, 71% were married; 89% were from MCH, and 11% were from FP clinics. Early PrEP use was positively influenced by encouragement from close confidants and effective concealment of PrEP pill-taking when necessary to avoid stigma or negative reactions from partners. Pregnancy helped conceal PrEP use because pill-taking is normalized during pregnancy, but concealment became more difficult postpartum. AGYW found keeping up with daily PrEP pill-taking challenging, and many noted only episodic periods of the HIV risk. Frequently testing HIV-negative reassured AGYW that PrEP was working and motivated persistence.
As PrEP programs scale-up in MCH/FP, it is increasingly important to enhance protection-effective PrEP use through approaches tailored to AGYW, with special considerations during pregnancy and postpartum.
在非洲环境中,青少年女孩和年轻妇女(AGYW)经常停止每日口服暴露前预防(PrEP)。我们探讨了在肯尼亚接受 PrEP 的 AGYW 中影响早期 PrEP 停药和持续使用的因素。
我们对 4 家母婴健康(MCH)和计划生育(FP)诊所的接受 PrEP 的 AGYW(年龄在 15-24 岁之间)进行了深入访谈。AGYW 是由护士在常规诊所就诊时确定的,并根据以下 4 个类别进行了有针对性的抽样:(1)接受了 PrEP 药丸,但从未开始使用 PrEP(例如,从未服用 PrEP 药丸),(2)在开始使用 PrEP 后 1 个月内停药,(3)在 1-3 个月内停药,(4)持续使用 PrEP 超过 3 个月。根据改变阶段模型,主题分析描述了对 PrEP 停药/持续使用的关键影响。
我们对接受药丸的 AGYW 进行了 93 次深入访谈。中位年龄为 22 岁,71%已婚;89%来自 MCH,11%来自 FP 诊所。得到亲密知己的鼓励和在必要时有效隐瞒 PrEP 药丸的服用,以避免来自伴侣的耻辱感或负面反应,这对早期 PrEP 的使用产生了积极影响。怀孕有助于隐瞒 PrEP 的使用,因为在怀孕期间服用药丸是正常的,但产后隐瞒变得更加困难。AGYW 发现每天服用 PrEP 药丸很困难,许多人只注意到艾滋病毒风险的间歇性时期。经常检测 HIV 阴性使 AGYW 相信 PrEP 有效,并激发了他们的坚持。
随着 PrEP 计划在 MCH/FP 中扩大规模,通过针对 AGYW 的方法来增强保护有效的 PrEP 使用变得越来越重要,特别是在怀孕期间和产后期间需要特别考虑。